iiinova — where your digital self keeps evolving

Daniel S. Levine @dslevine.bsky.social · 14/10/2026

Harith Rajagopalan, CEO of Fractyl Health, discusses its shift from type 2 diabetes to sustaining weight loss after patients stop GLP-1 medicines, the biology behind its approach, and how to turn the promise of a metabolic reset into a treatment. thebioreport.podbean.com/e/a-gut-leve...

000 0

Daniel S. Levine @dslevine.bsky.social · 07/10/2026

Rezera CEO Geoff McDonough discusses the role of inflammation in heart disease, the company’s phase 3 trial of ruvonoflast in peripheral artery disease, and its next-generation, brain-penetrant NLRP3 inhibitor in development for neuroinflammatory conditions. thebioreport.podbean.com/e/targeting-...

000 0

Daniel S. Levine @dslevine.bsky.social · 30/09/2026

Ryan Beal, CEO of Dyve Biosciences, discusses why acidity is an overlooked but foundational target in oncology, how its delivery technology may overcome the limitations of oral bicarbonate dosing, and indications beyond cancer that the company is pursuing. thebioreport.podbean.com/e/neutralizi...

000 0

Daniel S. Levine @dslevine.bsky.social · 24/09/2026

Steven Ringel, founder and CEO of Nome, discusses helping families and patient groups evaluate genetic-medicine options, shape development plans, and connect with partners to advance individualized therapies toward the clinic. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/en...

001 0

Daniel S. Levine @dslevine.bsky.social · 23/09/2026

Catharina Svanborg, chair of Hamlet Biopharma, discusses Alpha1H—an experimental synthetic peptide inspired by a protein complex in human breast milk—designed to target bladder tumor cells while sparing healthy tissue. thebioreport.podbean.com/e/enabling-p...

000 0

Daniel S. Levine @dslevine.bsky.social · 16/09/2026

Erik Ingelsson, CSO of Wave Life Sciences, explains how an RNA-based approach to fat loss could reshape obesity treatment—by targeting the biology that regulates fat breakdown and redefining what success looks like. thebioreport.podbean.com/e/targeting-...

000 0

Daniel S. Levine @dslevine.bsky.social · 09/09/2026

Jack Silberstein, CEO of Deck Bio, discusses the company’s efforts to create multi-target T-cell engagers that reach more cancer cells, reduce the likelihood that tumors will evade treatment, and minimize harm to healthy tissue. thebioreport.podbean.com/e/engineerin...

010 0

Daniel S. Levine @dslevine.bsky.social · 26/08/2026

Mayank Gandhi, co-founder and CEO of NEOK Bio, discusses the company’s bispecific ADC platform, its two clinical programs, and its strategy to develop more selective therapies for patients with advanced solid tumors. thebioreport.podbean.com/e/innovating...

000 0

Daniel S. Levine @dslevine.bsky.social · 19/08/2026

Alan Trounson Evinco discusses the company’s effort to develop NK cell-derived particles to cross the blood-brain barrier, curb neuroinflammation, and promote amyloid clearance in Alzheimer’s. thebioreport.podbean.com/e/targeting-...

000 0

Daniel S. Levine @dslevine.bsky.social · 12/08/2026

@gilead.com CMO Dietmar Berger on using targeted acquisitions to build platforms across solid tumors, autoimmune disease, and viral threats. thebioreport.podbean.com/e/how-gilead...

000 0

Daniel S. Levine @dslevine.bsky.social · 05/08/2026

Half of ischemic stroke patients face poor outcomes. Revalesio’s Greg Archambeau discusses how the company’s oxygenated saline therapy, RNS60, may help protect the brain after stroke, reduce tissue damage, and change the economics of stroke care. thebioreport.podbean.com/e/protecting...

000 0

Daniel S. Levine @dslevine.bsky.social · 29/07/2026

The autoimmune condition Type 1 diabetes is managed, not prevented. Zag Bio CEO Jason Cole discusses targeting immune tolerance via thymus-homing antibodies to induce Tregs. thebioreport.podbean.com/e/turning-th...

000 0

Daniel S. Levine @dslevine.bsky.social · 22/07/2026

Most drugs miss key GPCR targets. Christoffer Norn, CEO of SkapeBio discusses how the company is using AI-designed mini proteins to unlock them—combining strengths of biologics and small molecules to open new therapeutic frontiers. thebioreport.podbean.com/e/unlocking-...

000 0

Daniel S. Levine @dslevine.bsky.social · 15/07/2026

A-Alpha Bio’s David Younger discusses why more wet lab data and infrastructure will be needed for AI drug discovery than most people expect, why current public datasets fall short, and the company’s business model. thebioreport.podbean.com/e/addressing...

000 0

Daniel S. Levine @dslevine.bsky.social · 08/07/2026

Multispecific antibodies unlock new biology—but safety risks are often designed in. @labgeni_us' @AngusSinclair discusses how its AI platform engineers multi-specific T‑cell engagers that are both potent and selective in solid tumors. thebioreport.podbean.com/e/turning-mu...

000 0

Daniel S. Levine @dslevine.bsky.social · 01/07/2026

Acute ischemic stroke is common yet undertreated—few patients get thrombolytics or thrombectomy due to narrow treatment windows and bleeding risk. Basking Biosciences is developing a reversible vWF-targeting thrombolytic to expand access and safety. thebioreport.podbean.com/e/addressing...

000 0

Daniel S. Levine @dslevine.bsky.social · 24/06/2026

Plasma gelsolin, a natural regulator of inflammation depleted in severe illness, may offer a first-in-class, non-immunosuppressive way to tame cytokine storms in ARDS and beyond. Hear BioAegis CEO Susan Levinson on this pipeline-in-a-product. thebioreport.podbean.com/e/a-pipeline...

010 0

Daniel S. Levine @dslevine.bsky.social · 18/06/2026

High quality targets remain a bottleneck in drug discovery. Regeneron is addressing this by combining human genetics, proteomics, clinical data, and AI to scale target discovery. Aris Baras, head of the Regeneron Genetics Center, explains. thebioreport.podbean.com/e/building-a...

010 0

Daniel S. Levine @dslevine.bsky.social · 10/06/2026

Epigenetics may be cancer’s operating system. K36 is targeting a key enzyme that lets multiple myeloma cells grow, adapt, and resist treatment—aiming to re-sensitize tumors to existing drugs. A shift from chasing mutations to rewriting how cancer reads DNA. thebioreport.podbean.com/e/stopping-s...

000 0

Daniel S. Levine @dslevine.bsky.social · 03/06/2026

Most antibodies act as antagonists—but biology isn’t that simple. Metaphore’s function-first platform uses live-cell data + ML to design antibodies that agonize, bias, or multi-target pathways. CEO Angela Hwang explains: thebioreport.podbean.com/e/rewriting-...

020 0

Daniel S. Levine @dslevine.bsky.social · 27/05/2026

Cells constantly sense and respond to stress—adapting, recovering, or dying. Soley uses AI to map these responses at scale, unlocking “undruggable” targets. Soley's Yerem Yeghiazarians discusses their platform, pipeline, and first-in-class candidates. thebioreport.podbean.com/e/mapping-ce...

000 0

Daniel S. Levine @dslevine.bsky.social · 20/05/2026

Eric Elenko, president and co founder of PureTech, discusses the company’s disciplined approach to rescuing promising but discontinued therapeutics, its hub and spoke structure, and how this model can turn partially derisked assets into commercial successes. thebioreport.podbean.com/e/turning-ab...

000 0

Daniel S. Levine @dslevine.bsky.social · 13/05/2026

Most cancer therapies hit 1 or 2 pathways, giving tumors a chance to adapt. Nuago CEO Robert Schickel discusses how his company is developing short RNAs to silence multiple survival genes at once—aiming for more durable tumor killing with less toxicity. thebioreport.podbean.com/e/targeting-...

000 0

Daniel S. Levine @dslevine.bsky.social · 06/05/2026

Crystalis CEO James Mackay discusses gout, why therapies often fail to get uric acid to target levels, and how the company’s next generation URAT1 inhibitor may fill the treatment gap and change daily life for patients living with moderate to severe gout. thebioreport.podbean.com/e/addressing...

000 0

Daniel S. Levine @dslevine.bsky.social · 29/04/2026

When inflammation spirals out of control, traditional drugs often don’t work. Mesoblast’s Ryoncil—the first MSC therapy in the US—targets GVHD in children. CEO Silviu Itescu discusses how MSCs can calm cytokine storms and what’s next for the platform. 🎧 thebioreport.podbean.com/e/an-off-the...

000 0

Daniel S. Levine @dslevine.bsky.social · 22/04/2026

Most MS drugs control relapses—but don’t stop the neurodegeneration driving long-term disability. Daniel Vitt, CEO of Immunic, discusses how his company’s experimental once-daily oral therapy targets both inflammation and neuronal damage. thebioreport.podbean.com/e/slowing-di...

000 0

Daniel S. Levine @dslevine.bsky.social · 15/04/2026

Marc de Garidel, of Abivax, discusses how a once-failed HIV drug evolved into a late stage oral IBD therapy that may deliver durable remission, how it acts upstream of key inflammatory pathways, and its potential in a crowded but underserved IBD market. thebioreport.podbean.com/e/tuning-rat...

000 0

Daniel S. Levine @dslevine.bsky.social · 01/04/2026

Alzheimer’s R&D has focused on memory loss—but for many families, the breaking point is psychosis: hallucinations and delusions that make home care impossible. Acadia’s R&D head Elizabeth Thompson discusses new approaches to treating Alzheimer’s psychosis. thebioreport.podbean.com/e/targeting-...

000 0

Daniel S. Levine @dslevine.bsky.social · 25/03/2026

Attorney Harrison James of Wisner Baum discusses a national civil RICO class action against Takeda and Eli Lilly, what it took to apply a statute intended for mobsters to drugmakers, and the implications the case may have for the pharmaceutical industry. thebioreport.podbean.com/e/a-class-ac...

000 0

Daniel S. Levine @dslevine.bsky.social · 18/03/2026

Ben Zeskind, CEO of Immuneering, discusses how the company is using its informatics-driven dosing regimen to re-engineer targeted cancer therapy so it extends survival, delays resistance, and is better tolerated. thebioreport.podbean.com/e/outsmartin...

000 0

Daniel S. Levine @dslevine.bsky.social · 11/03/2026

Richard Freed, CEO of RheumaGen, discusses role of HLA genes in autoimmune diseases, how the company’s gene-editing therapies work, and its lead program in rheumatoid arthritis. thebioreport.podbean.com/e/editing-aw...

000 0

Daniel S. Levine @dslevine.bsky.social · 04/03/2026

Fangning Zhang of McKinsey’s Shanghai office explains why Asia is becoming a biopharma innovation powerhouse, how it could lower drug development costs, and why treating Asia as optional risks missing the next wave of global R&D. Podcast: thebioreport.podbean.com/e/why-asia-i...

000 0

Daniel S. Levine @dslevine.bsky.social · 25/02/2026

Leukemia survivor and @columbiauniversity.bsky.social hematologist-oncologist Aaron Viny is reimagining blood cancer care—moving from blunt chemo to precision strategies that rewire malignant cells, epigenetic programs, and their ecosystems. thebioreport.podbean.com/e/reprogramm...

000 0

Daniel S. Levine @dslevine.bsky.social · 18/02/2026

Terns Pharmaceuticals' CEO Amy Burroughs discusses a strategic shift from metabolic disease to focus on the company's experimental therapy for chronic myeloid leukemia and how she is charting a clear path toward a broader oncology future. thebioreport.podbean.com/e/a-strategi...

010 0

Daniel S. Levine @dslevine.bsky.social · 11/02/2026

Ron Cooper, CEO of enGene, discusses the company’s experimental gene therapy for non–muscle invasive bladder cancer, and how its dual payload is meant to activate both an innate and adaptive immune response in the bladder. thebioreport.podbean.com/e/a-one-two-...

000 0

Daniel S. Levine @dslevine.bsky.social · 04/02/2026

Michael Roberts, CEO of Adaptin Bio, discusses the company’s platform technology that uses patient-derived T cells as delivery vehicles for targeted biologics that cross the blood-brain barrier to treat glioblastoma. thebioreport.podbean.com/e/reprogramm...

000 0

Daniel S. Levine @dslevine.bsky.social · 28/01/2026

Xaira's Marc Tessier-Lavigne discusses applying end-to-end AI across target discovery, molecular design, and patient stratification; the company’s $1 billion in funding, and how it seeks to enable a new generation of scientists. thebioreport.podbean.com/e/a-billion-...

010 0

Daniel S. Levine @dslevine.bsky.social · 21/01/2026

Faraz Choudhury of Immuto Scientific discusses the company’s AI-enabled structural surfaceomics platform, how it allows drugs to selectively home in on diseased cells while sparing normal ones, and its plans to extend its science beyond cancer. thebioreport.podbean.com/e/finding-ne...

000 0

Daniel S. Levine @dslevine.bsky.social · 14/01/2026

Marc Iacobucci of NanOlogy discusses how the company’s platform technology enables high-concentration dosing inside tumors that destroys cancer cells, stimulates immune responses, and spares patients the debilitating effects of systemic chemotherapy. thebioreport.podbean.com/e/targeting-...

010 0

Daniel S. Levine @dslevine.bsky.social · 07/01/2026

Valerie Daggett, CEO of AltPep, discusses the relationship between α-sheet oligomers and the onset of Alzheimer’s disease, the company’s synthetic peptides to target them, and the potential for its platform to treat a broader set of amyloid diseases. thebioreport.podbean.com/e/an-effort-...

000 0

Daniel S. Levine @dslevine.bsky.social · 05/01/2026

Matt Wood @oxfordharrington.bsky.social discusses the challenges of rare disease drug development, the resources the center brings to address them, and the mechanisms it has established to accelerate therapeutic development. @globalgenes.bsky.social #RARECast globalgenes.org?post_type=ra...

000 0

Daniel S. Levine @dslevine.bsky.social · 31/12/2025

Adam Feuerstein, senior biotech writer for STAT, joins us for our annual review-preview edition to discuss the noteworthy trends in the biotech sector in 2025, and what’s in store at the upcoming JPMorgan Healthcare Conference and beyond in 2026. thebioreport.podbean.com/e/the-year-i...

000 0

Daniel S. Levine @dslevine.bsky.social · 24/12/2025

Adam Gridley, CEO of Allay Therapeutics, discusses post-surgical pain, the need for alternatives to opioids, and the company’s experimental, implanted, extended-release analgesic. thebioreport.podbean.com/e/developing...

000 0

Daniel S. Levine @dslevine.bsky.social · 17/12/2025

Kang Hsu, CMO of Canary Speech, discusses how its diagnostic tool works to diagnose neurological and psychiatric conditions using vocal biomarkers, how it is embedded invisibly into clinical workflows, and how the company is driving physician adoption. thebioreport.podbean.com/e/leveraging...

010 0

Daniel S. Levine @dslevine.bsky.social · 10/12/2025

Tim Sweeney, CEO of Inflammatix, Inc., discusses the company’s point-of-care test for sepsis, how it works; and how it is used in an ER setting to determine who needs antibiotics, ICU‑level care, or a broader diagnostic workup. thebioreport.podbean.com/e/determinin...

010 0

Daniel S. Levine @dslevine.bsky.social · 03/12/2025

Atta Behfar, co-founder and CEO of Rion, discusses how the company’s purified exosome products work, their potential as scalable and cost-effective regenerative therapies, and how they avoid the immune issues that have long hampered cell-based approaches. thebioreport.podbean.com/e/separating...

000 0

Daniel S. Levine @dslevine.bsky.social · 26/11/2025

Mo Jain, chief scientific officer of Sapient, discusses how its technology bridges the gap from discovery to clinical development, accelerates drug development timelines, and expands opportunities to drug previously undruggable targets. thebioreport.podbean.com/e/rewriting-...

000 0

Daniel S. Levine @dslevine.bsky.social · 19/11/2025

Dan Schmitt, CEO of Actuate Therapeutics, discusses the company’s experimental therapy elraglusib’s potential to overcome chemoresistance, its recent clinical successes in metastatic pancreatic cancer, and the drug’s unique multimodal mechanism. thebioreport.podbean.com/e/overcoming...

011 0

Daniel S. Levine @dslevine.bsky.social · 12/11/2025

Theresa Heah, CEO of Eyexora, discusses the hub-and-spoke business model, the company’s initial assets in-licensed from the Singapore Eye Research Institute, and how it identifies early-stage candidates with high potential. thebioreport.podbean.com/e/a-hub-and-...

010 0

Daniel S. Levine @dslevine.bsky.social · 05/11/2025

Brian Weitzner, co-founder of OpenFold, discusses the collaborative effort to develop software and AI tools to predict the 3D structure of proteins, how its open licensing model ensures broad accessibility, and how it stacks up against AlphaFold. thebioreport.podbean.com/e/an-ai-coll...

021 0